138 related articles for article (PubMed ID: 1550085)
21. Clinical experience of fotemustine, cisplatin and high dose tamoxifen in patients with metastatic malignant melanoma.
Semb KA; Aamdal S; Bohmann T; Lucas C; Gerard B
Melanoma Res; 1998 Dec; 8(6):565-72. PubMed ID: 9918419
[TBL] [Abstract][Full Text] [Related]
22. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
[TBL] [Abstract][Full Text] [Related]
23. Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
Mohr P; Makki A; Breitbart E; Schadendorf D
Melanoma Res; 1998 Apr; 8(2):166-9. PubMed ID: 9610871
[TBL] [Abstract][Full Text] [Related]
24. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
25. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
[TBL] [Abstract][Full Text] [Related]
26. Fotemustine-dacarbazine combinations in the treatment of metastatic melanoma.
Merimsky O; Chaitchik S
Eur J Cancer; 1993; 29A(3):481-2. PubMed ID: 8398358
[No Abstract] [Full Text] [Related]
27. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
28. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma--an effective combination with unexpected toxicity.
Aamdal S; Gerard B; Bohman T; D'Incalci M
Eur J Cancer; 1992; 28(2-3):447-50. PubMed ID: 1591062
[TBL] [Abstract][Full Text] [Related]
29. Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
Andersson R; Ake Hofer P; Riklund-Ahlström K; Henriksson R
Melanoma Res; 2003 Feb; 13(1):87-91. PubMed ID: 12569290
[TBL] [Abstract][Full Text] [Related]
30. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
Terheyden P; Becker JC; Kämpgen E; Bröcker EB
Melanoma Res; 2000 Oct; 10(5):475-82. PubMed ID: 11095409
[TBL] [Abstract][Full Text] [Related]
31. Primary malignant melanoma of the vagina: case report.
Stellato G; Iodice F; Casella G; Fortuna G; Tramontana R; di Bonito M; Tramontana S
Eur J Gynaecol Oncol; 1998; 19(2):186-8. PubMed ID: 9611064
[TBL] [Abstract][Full Text] [Related]
32. Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitization for advanced melanoma of the extremities.
Rossi CR; Lejeune FJ; Pontes L; Foletto M; De Salvo GL; Pilati PL; Mocellin S; Ribeiro M; Lopes M; Lise M
Melanoma Res; 2003 Jun; 13(3):293-7. PubMed ID: 12777985
[TBL] [Abstract][Full Text] [Related]
33. Ipilimumab with fotemustine in metastatic melanoma.
Garbe C
Lancet Oncol; 2012 Sep; 13(9):851-2. PubMed ID: 22894885
[No Abstract] [Full Text] [Related]
34. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma.
Pontes L; Lopes M; Ribeiro M; Santos JG; Azevedo MC
Melanoma Res; 1997 Oct; 7(5):417-9. PubMed ID: 9429225
[TBL] [Abstract][Full Text] [Related]
35. High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study.
Guida M; Cramarossa A; Fistola E; Porcelli M; Giudice G; Lubello K; Colucci G
J Transl Med; 2010 Nov; 8():115. PubMed ID: 21067582
[No Abstract] [Full Text] [Related]
36. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
Daponte A; Signoriello S; Maiorino L; Massidda B; Simeone E; Grimaldi AM; Caracò C; Palmieri G; Cossu A; Botti G; Petrillo A; Lastoria S; Cavalcanti E; Aprea P; Mozzillo N; Gallo C; Comella G; Ascierto PA;
J Transl Med; 2013 Feb; 11():38. PubMed ID: 23402397
[TBL] [Abstract][Full Text] [Related]
37. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
38. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma.
Guida M; Latorre A; Mastria A; De Lena M
Eur J Cancer; 1996 Apr; 32A(4):730-3. PubMed ID: 8695281
[TBL] [Abstract][Full Text] [Related]
39. [Hepatic intra-arterial bio-chemotherapy for the treatment of melanoma patients with liver metastasis: a phase II clinical study].
Cui CL; Chi ZH; Yuan XQ; Lian HY; Si L; Guo J
Ai Zheng; 2008 Aug; 27(8):845-50. PubMed ID: 18710619
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
